Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

大约70%的晚期乳腺癌为激素受体阳性HER2阴性，主要依靠内分泌治疗和化疗。对于内分泌治疗耐药患者，虽然细胞周期蛋白依赖性激酶CDK4/6抑制剂有效，但是仍然可能发生耐药。乳腺癌命运第四交响曲（DESTINY-Breast04）研究已经证实，德曲妥珠 ...

The combination of trastuzumab biosimilar and pertuzumab with chemotherapy was effective in treating HER2-positive breast cancer, offering high safety and affordability. HER2-positive breast cancer ...

The DESTINY-Breast12 trial revealed that trastuzumab deruxtecan (T-DXd) effectively targets brain metastases in HER2-positive ...

Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy. We conducted ...

In a 10-year analysis of the ShortHER trial, high tumor-infiltrating lymphocytes were associated with improved survival in ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase I for Metastatic Breast Cancer.

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan ...